LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotechnology consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is an Investor Relations consultancy that provides equity research to clients in Healthcare LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in Pharmaceuticals. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Healthcare Investor consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Pharmaceutical Investor consultancy that provides equity research to clients in Medical Devices.

Web developed by Bolinger web design

Our Distribution


Anthera Completes PEARL-SC Interim Analysis


« Back to News


-PEARL-SC Trial Continues as Planned-

-VISTA-16 Interim Analysis to Occur Next Week-


Report is Available for Download at: www.lifesciadvisors.com/clients/anthera

Yesterday morning, Anthera Pharmaceuticals (NASDAQ: ANTH) issued a press release and announced the completion of the fourth PEARL-SC Data Safety Monitoring Board (DSMB) review and an interim efficacy analysis by an independent statistician. We report that both parties recommend that the Phase IIb PEARL-SC Study continues as planned.

The Phase IIb PEARL-SC Study (n=547) is examining the ability of weekly and monthly subcutaneous injections of blisibimod to provide therapeutic benefit to patients with Lupus. The primary endpoint is clinical improvement at 24 weeks in a SLE responder index.

DSMB Review Recommends that Study Continue as Planned. With regards to the fourth DSMB safety review for the PEARL-SC study, the board recommended that the study continued as planned with no modifications to study protocol. This result was expected by many investors, but it is still a good sign of the continued strong safety profile of blisibimod.

« Back to News

Contact Us   |   About Us   |   Privacy Policy   |   Disclaimer  |   Careers

©2014 LifeSci Advisors, LLC. All Rights Reserved.

email


Web developed by Bolinger web design